4DMT Secures Up To $200M Non-Dilutive Credit Facility, Extending Cash Runway
FDMT has more than doubled off its 52-week low of $3.68 on elevated volume (2.5× avg).
Summary
4D Molecular Therapeutics secured a strategic credit facility for up to $200 million from Hercules Capital, with an initial draw of $20 million. This non-dilutive financing significantly enhances the company's financial strength and operational flexibility, extending its cash runway beyond the previously projected second half of 2028. The capital will support the advancement of its gene therapy pipeline, including the Phase 3 development of 4D-150 for wet AMD and DME. This facility diversifies their capital structure, complementing the $400 million universal shelf registration filed in May. Hercules Capital (HTGC) is the lender in this agreement.
At the time of this announcement, FDMT was trading at $11.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $606.4M. The 52-week trading range was $3.68 to $12.34. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.